Features Partner Sites Information LinkXpress
Sign In
Demo Company

Clinical Trial Failure May Be Counteracted by Biomarkers in the Future

By BiotechDaily International staff writers
Posted on 25 Dec 2012
Print article
Biomarkers could someday decrease the amount of failed clinical trials, if fully supported by the medical community, according to new market research.

The new report, published by healthcare market research company GBI Research (New York, NY, USA), noted that biomarkers can be utilized in all phases of drug discovery to determine the safety and effectiveness of candidate drugs. They are able to identify a number of lead candidates and drug targets, while predicting which drugs will not work, saving drug discovery costs and research time in the early stages of development.

With surging drug attrition rates, the proportion of drugs gaining regulatory approval has been reduced to only 8%, and most failures during the drug discovery process happen in the late clinical trial stages, leading to a considerable loss of money, time, and effort and patients are left untreated. The year 2007 saw the fewest drug approvals since 1983, alarming the pharmaceuticals sector and creating a demand for drug discovery techniques that can more effectively predict failures.

Biomarkers have several benefits over traditional drug discovery approaches--for example, they are highly sensitive and selective in their approach, and their application in drug discovery makes the process robust and time-efficient.

However, in spite of benefits of biomarkers over conventional methods, most pharmaceutical companies, academic institutions, and clinical practitioners do not use them extensively in drug discovery due to a lack of awareness among the academic community. Although essential research data are available, there is a scarcity of intelligent and novel technologic developments such as technology systems and biomarker assays, and this is restraining growth of the global biomarkers market.

Funding problems also pose a challenge for the necessary R&D of biomarkers. The development process of biomarkers requires strong technical expertise and the combination of genomic, proteomic, and transcriptomics-based technologies, which are very expensive and require huge funding. However, many funding organizations require strong clinical data and validation to provide funds for research and testing phases, and the initial gathering of data itself requires funding, thereby forming a vicious circle. The biomarker discovery and confirmation procedure is also long and burdensome, with only 1% of all biomarkers found reaching the validation stage.

Until the profile of biomarkers is adequately increased, and enough money is invested, the pharmaceutical industry will not see the benefits of biomarkers in action, in spite of the billion-dollar clinical trial industry they could potentially transform.

GBI Research is a provider of business intelligence reports, providing actionable data and forecasts based on the insights of industry leaders.

Related Links:

GBI Research

Print article



view channel
Image: Left: Green actin fibers create architecture of the cell. Right: With cytochalasin D added, actin fibers disband and reform in the nuclei (Photo courtesy of the University of North Carolina).

Actin in the Nucleus Triggers a Process That Directs Stem Cells to Mature into Bone

A team of cell biologists has discovered why treatment of mesenchymal stem cells (MSCs) with the mycotoxin cytochalasin D directs them to mature into bone cells (osteoblasts) rather than into fat cells... Read more


view channel

Molecular Light Shed on “Dark” Cellular Receptors

Scientists have created a new research tool to help find homes for orphan cell-surface receptors, toward better understanding of cell signaling, developing new therapeutics, and determining causes of drug side-effects. The approach may be broadly useful for discovering interactions of orphan receptors with endogenous, naturally... Read more

Lab Technologies

view channel
Image: The new ambr 15 fermentation micro-bioreactor system was designed to enhance microbial strain screening applications (Photo courtesy of Sartorius Stedim Biotech).

New Bioreactor System Streamlines Strain Screening and Culture

Biotechnology laboratories working with bacterial cultures will benefit from a new automated micro bioreactor system that was designed to enhance microbial strain screening processes. The Sartorius... Read more
Copyright © 2000-2015 Globetech Media. All rights reserved.